Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.79−0.06 (-7.50%)
Close on Nov 19, 2026Market cap $101.55MP/E –Yield –
Organogenesis net income
Net income is the profit left for shareholders after every expense, interest and tax.
Organogenesis's net income for the twelve months ending Jun 30, 2026 was -$84.16M. For fiscal 2025 it was $37.03M, up 4201.0% from the year before. The highest annual figure on record is $94.20M in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.03M | +4201.0% |
| FY2024 | Dec 31, 2024 | $861.00K | -82.6% |
| FY2023 | Dec 31, 2023 | $4.95M | -68.2% |
| FY2022 | Dec 31, 2022 | $15.53M | -83.5% |
| FY2021 | Dec 31, 2021 | $94.20M | +446.6% |
| FY2020 | Dec 31, 2020 | $17.23M | – |
| FY2019 | Dec 31, 2019 | -$38.71M | – |
| FY2018 | Dec 31, 2018 | -$64.83M | – |
| FY2017 | Dec 31, 2017 | -$8.39M | – |
| FY2016 | Dec 31, 2016 | -$16.99M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$96.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$53.16M | – |
| Q4 FY2025 | Dec 31, 2025 | $43.70M | +469.5% |
| Q3 FY2025 | Sep 30, 2025 | $21.57M | +74.9% |
| Q2 FY2025 | Jun 30, 2025 | -$9.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.84M | – |
| Q4 FY2024 | Dec 31, 2024 | $7.67M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.33M | +289.4% |
| Q2 FY2024 | Jun 30, 2024 | -$17.04M | -420.6% |
| Q1 FY2024 | Mar 31, 2024 | -$2.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$568.00K | -107.6% |
| Q3 FY2023 | Sep 30, 2023 | $3.17M | +1373.0% |
| Q2 FY2023 | Jun 30, 2023 | $5.32M | -39.2% |
| Q1 FY2023 | Mar 31, 2023 | -$2.97M | – |
| Q4 FY2022 | Dec 31, 2022 | $7.49M | -85.3% |
| Q3 FY2022 | Sep 30, 2022 | $215.00K | -98.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.74M | -57.7% |
| Q1 FY2022 | Mar 31, 2022 | -$913.00K | -109.2% |
| Q4 FY2021 | Dec 31, 2021 | $51.00M | +178.4% |
| Q3 FY2021 | Sep 30, 2021 | $12.58M | -39.4% |
| Q2 FY2021 | Jun 30, 2021 | $20.69M | – |
| Q1 FY2021 | Mar 31, 2021 | $9.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $18.32M | – |
| Q3 FY2020 | Sep 30, 2020 | $20.76M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.74M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.67M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$20.01M | -64648.4% |
| Q1 FY2018 | Mar 31, 2018 | -$22.49M | -1088.5% |
| Q4 FY2017 | Dec 31, 2017 | -$4.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $31.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $2.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$178.16K | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.49K | – |
See a number that looks wrong?